Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
Carlyle Group Inc. - 18 Feb 2026 SCHEDULE 13D/A Report for Jasper Therapeutics, Inc. Voting Common Stock, par value $0.0001 per share (JSPR)
- Filing manager
- Carlyle Group Inc.
- Reporting owner
- The Carlyle Group Inc.
- Beneficially owned shares
- 1,088,310 shares
- Class ownership
- 3.8%
- Large-stake signal
-
Ownership
3.8%
Beneficial ownership of this reported class.
Shares
1,088,310 shares
Shares beneficially owned as disclosed.
Event date
18 Feb 2026
Date tied to the ownership event or amendment.
Accepted by SEC
18 Feb 2026
EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Symbol
- JSPR
- Shares outstanding
- 28,639,737 shares
- Form type
- SCHEDULE 13D/A
- Accepted by SEC
- 18 Feb 2026, 17:29:20 UTC
- Event date
- 18 Feb 2026
- SEC filing
- View on sec.gov
Ownership signal
2 signals
Subject security
2 source fields
Source evidence
4 source fields
Key filing fact
Carlyle Group Inc. disclosed 3.8% ownership in Jasper Therapeutics, Inc. Voting Common Stock, par value $0.0001 per share (JSPR) on 18 Feb 2026.
Key facts
- Carlyle Group Inc. filed SCHEDULE 13D/A for Jasper Therapeutics, Inc. Voting Common Stock, par value $0.0001 per share (JSPR).
- Disclosed ownership: 3.8%.
- Date of event: 18 Feb 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 18 Feb 2026, 17:29.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (10)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Carlyle Group Inc. | 3.8% | 1,088,310 | 0 | 1,088,310 | /s/ Anne K. Frederick | Anne K. Frederick, Corporate Secretary | 0001527166 |
| Carlyle Holdings I GP Inc. | 3.8% | 1,088,310 | 0 | 1,088,310 | /s/ Anne K. Frederick | Anne K. Frederick, Managing Director | 0001548626 |
| Carlyle Holdings I GP Sub L.L.C. | 3.8% | 1,088,310 | 0 | 1,088,310 | By: Carlyle Holdings I GP Inc., its sole member, /s/ Anne K. Frederick | Anne K. Frederick, Managing Director | 0001548627 |
| Carlyle Holdings I L.P. | 3.8% | 1,088,310 | 0 | 1,088,310 | /s/ Anne K. Frederick | Anne K. Frederick, Managing Director | 0001548628 |
| CG Subsidiary Holdings L.L.C. | 3.8% | 1,088,310 | 0 | 1,088,310 | /s/ Anne K. Frederick | Anne K. Frederick, Managing Director | 0001790577 |
| TC Group, L.L.C. | 3.8% | 1,088,310 | 0 | 1,088,310 | /s/ Anne K. Frederick | Anne K. Frederick, Managing Director | 0000933790 |
| Carlyle Investment Management L.L.C. | 3.8% | 1,088,310 | 0 | 1,088,310 | /s/ Anne K. Frederick | Anne K. Frederick, Managing Director | 0001354120 |
| Carlyle Genesis UK LLC | 3.8% | 1,088,310 | 0 | 1,088,310 | By: Carlyle Investment Management L.L.C., its sole member, /s/ Anne K. Frederick | Anne K. Frederick, Managing Director | 0001941860 |
| Abingworth LLP | 3.8% | 1,088,310 | 0 | 1,088,310 | /s/ Emma O'Reilly | Emma O'Reilly, Authorized Signatory | 0001397144 |
| Abingworth Bioventures VII LP | 3.8% | 1,088,310 | 0 | 1,088,310 | /s/ Emma O'Reilly | Emma O'Reilly, Authorized Signatory | 0001688313 |
CIK / CUSIP context first